1,193,626 Shares in Apogee Therapeutics Inc. $APGE Acquired by Jupiter Topco LLC

Jupiter Topco LLC purchased a new stake in Apogee Therapeutics Inc. (NASDAQ:APGE) during the 2nd quarter, HoldingsChannel reports. The fund purchased 1,193,626 shares of the company’s stock, valued at approximately $158,402,000.

A number of other large investors have also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after acquiring an additional 694 shares during the period. Millennium Management LLC grew its holdings in shares of Apogee Therapeutics by 100.0% in the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after purchasing an additional 130,164 shares during the last quarter. Creative Planning bought a new stake in shares of Apogee Therapeutics in the 2nd quarter worth about $392,000. Legal & General Group Plc increased its position in shares of Apogee Therapeutics by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after purchasing an additional 1,907 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Apogee Therapeutics by 10,570.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,768 shares of the company’s stock worth $945,000 after purchasing an additional 21,564 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Trading Up 0.1%

Shares of NASDAQ APGE opened at $134.95 on Thursday. Apogee Therapeutics Inc. has a 1-year low of $35.39 and a 1-year high of $134.99. The company has a 50-day moving average of $132.21 and a two-hundred day moving average of $97.78. The company has a market cap of $8.39 billion, a PE ratio of -31.09 and a beta of 0.34.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.07). As a group, equities research analysts forecast that Apogee Therapeutics Inc. will post -4.47 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00. Following the completion of the sale, the insider directly owned 179,248 shares of the company’s stock, valued at approximately $23,768,284.80. This trade represents a 12.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 80,000 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $132.54, for a total value of $10,603,200.00. Following the sale, the chief executive officer owned 1,015,987 shares of the company’s stock, valued at approximately $134,658,916.98. The trade was a 7.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 162,900 shares of company stock worth $20,344,950 over the last quarter. Corporate insiders own 24.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on APGE. TD Cowen lowered shares of Apogee Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd. BTIG Research lowered shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 12th. Truist Financial lifted their target price on shares of Apogee Therapeutics from $81.00 to $135.00 and gave the company a “hold” rating in a research note on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Friday, July 17th. Finally, Citigroup lowered Apogee Therapeutics from a “buy” rating to a “neutral” rating and increased their price target for the stock from $125.00 to $135.00 in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $124.43.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.